Studies have demonstrated that the ALK‐5 inhibitor compound SB‐525334, which targets TGF‐β signaling, prevented both the induction and progression of pulmonary fibrosis, when administered either prophylactically (Higashiyama et al. 2007) or therapeutically (Peng et al. 2013) to bleomycin‐challenged mice. The gene discussed is TGFB1; the disease is pulmonary fibrosis.